Listen
Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
-
Clinical Benefit
| Substantial |
The actual benefit of OZURDEX 700 μg intravitreal implant in applicator is substantial. |
Clinical Added Value
| minor |
OZURDEX 700 μg intravitreal implant in applicator offers a minor improvement in actual benefit (IAB IV) in the management of the treatment of macular oedema and oedema following either branch retinal vein occlusion or central retinal vein occlusion. |
English version
Contact Us
Évaluation des médicaments
